Shri Sai Balaji Pharmatech Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 30-05-2024
- Paid Up Capital ₹ 5.00 M
as on 30-05-2024
- Company Age 9 Year, 7 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 3.32 Cr
as on 30-05-2024
- Revenue -35.23%
(FY 2023)
- Profit -27.31%
(FY 2023)
- Ebitda 331.05%
(FY 2023)
- Net Worth 1.08%
(FY 2023)
- Total Assets -13.38%
(FY 2023)
About Shri Sai Balaji Pharmatech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 5.00 M.
The company currently has active open charges totaling ₹3.32 Cr.
Chhaggan Lal and Anil Kumar serve as directors at the Company.
- CIN/LLPIN
U24232CH2015PTC035542
- Company No.
035542
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 May 2015
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, Chandigarh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shri Sai Balaji Pharmatech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Chhaggan Lal  | Director | 30-May-2015 | Current |
| Anil Kumar | Director | 01-Nov-2016 | Current |
Financial Performance of Shri Sai Balaji Pharmatech.
Shri Sai Balaji Pharmatech Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 35.23% decrease. The company also saw a substantial fall in profitability, with a 27.31% decrease in profit. The company's net worth moved up by a moderate rise of 1.08%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shri Sai Balaji Pharmatech?
Unlock access to Shri Sai Balaji Pharmatech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Curehealth Pharmaceuticals Private LimitedActive 11 years 3 monthsChhaggan Lal and Anil Kumar are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Indian Bank Creation Date: 20 May 2022 | ₹3.13 M | Open |
Indian Bank Creation Date: 04 Feb 2022 | ₹0.90 M | Open |
Indian Bank Creation Date: 27 Feb 2017 | ₹2.92 Cr | Open |
How Many Employees Work at Shri Sai Balaji Pharmatech?
Shri Sai Balaji Pharmatech has a workforce of 1 employees as of Mar 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shri Sai Balaji Pharmatech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shri Sai Balaji Pharmatech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
